Radioimmunotherapy for NHL: Experience of 90Y-Ibritumomab tiuxetan in clinical practice

Leukemia and Lymphoma

Volumn 44, Issue SUPPL. 4, 2003, Pages

  Hagenbeek, Anton ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Ibritumomab tiuxetan; NHL; Radioimmunotherapy; Zevalin

Indexed keywords

ALKYLATING AGENT; CD20 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; YTTRIUM 90;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALGORITHM; ANEMIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BACTERIAL INFECTION; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHELATION; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; COVALENT BOND; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; DYSPNEA; ECCHYMOSIS; EXPERIENCE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HOT FLUSH; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOTHERAPY; THROAT DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR VOLUME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 1342266244     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001616944     Document Type: Article

References (50)

1. Edwards, B.K., Howe, H.L., Ries, L.A., Thun, M.J., Rosenberg, H.M., Yancik, R., et al. (2002) "Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden", Cancer, 94, 2766-2792.
2. Ries, L.A., Eisner, M.P., Kosary, C.L., Hankey, B.F., Miller, B.A., Clegg, L., et al. (2003) SEER Cancer Statistics Reriew, 1975-2000, Bethesda, MD: National Cancer Institute.
3. Nakamura, K., Kunitake, N., Kimura, M., Shioyama, Y., Terashima, H. and Masuda, K. (2000) "Radiotherapy for localized relapse in patients with non-Hodgkin's lymphoma: a preliminary report", Radiat. Med., 18, 245-248.
4. Marromatis, B.H. and Cheson, B.D. (2001) "New strategies for the treatment of indolent non-Hodgkin's lymphomas", Oncology Spectrums, 2, 706-716.
5. Fisher, R.I. (2000) "Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma", Semin. Oncol., 27, 2-8.
6. Hagenbeek, A. and Kluin, P.M. (1999) Non-Hodgkin's lymphomas. In: Textbook of Malignant Haematology, edited by L. Degos, D.C. Linch and B. Lowenberg. Pp. 635-684. London: Martin Dunitz, London.
7. Horning, S.J. (1993) "Natural history of and therapy for the indolent non-Hodgkin's lymphomas", Semin. Oncol., 20, 75-88.
8. Press, O.W., Leonard, J.P., Coiffier, B., Levy, R. and Timmerman, J. (2001) "Immunotherapy of Non-Hodgkin's lymphomas", Hematology (Am. Soc. Hematol. Educ. Program), 221-240.
9. Vose, J.M. (2000) "Therapeutic uses of MAbs directed against CD20", Cytotherapy, 2, 455-461.
10. Hohenstein, M. (2002) "Immunotherapy: a novel treatment for Non-Hodgkin's lymphoma", Semin. Oncol. Nurs., 18, 10-15.
11. Juweid, M.E. (2002) "Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice", J. Nucl. Med., 43, 1507-1529.
12. Cheson, B.D. (2003) "Radioimmunotherapy of non-Hodgkin lymphomas", Blood, 101, 391-398.
13. Chanan-Khan, A. and Czuczman, M.S. (2002) "Radioimmunotherapy in non-Hodgkin lymphoma", Curr. Opin. Oncol., 14, 484-489.
14. Dillman, R.O. (2002) "Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma", J. Clin. Oncol., 20, 3545-3557.
15. Meredith, R.F. and Knox, S.J. (2001) "Radioimmunotherapy of B-cell NHL", Curr. Pharm. Biotechnol., 2, 327-339.
16. Postema, E.J., Boerman, O.C., Oyen, W.J., Raemaekers, J.M. and Corstens, F.H. (2001) "Radioimmunotherapy of B-cell non-Hodgkin's lymphoma", Eur. J. Nucl. Med., 28, 1725-1735.
17. DeNardo, G.L., O'Donnell, R.T. and DeNardo, S.J. (2001) "Radiolabeled anti-lymphoma antibodies", Cancer Chemother. Biol. Response Modif., 19, 297-308.
18. Zelenetz, A.D. (1999) "Radioimmunotherapy for lymphoma", Curr. Opin. Oncol., 11, 375-380.
19. Press, O.W., Appelbaum, F., Ledbetter, J.A., Martin, P.J., Zarling, J., Kidd, P., et al. (1987) "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas", Blood, 69, 584-591.
20. Kaminski, M.S., Zasadny, K.R., Francis, I.R., Milik, A.W., Ross, C.W., Moon, S.D., et al. (1993) " Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody", N. Engl. J. Med., 329, 459-465.
21. Kaminski, M.S., Zasadny, K.R., Francis, I.R., Fenner, M.C., Ross, C.W., Milik, A.W., et al. (1996) "Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma", J. Clin. Oncol., 14, 1974-1981.
22. Kaminski, M.S., Estes, J., Zasadny, K.R., Francis, I.R., Ross, C.W., Tuck, M., et al. (2000) "Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood, 96, 1259-1266.
23. Vose, J.M., Wahl, R.L., Saleh, M., Rohatiner, A.Z., Knox, S.J., Radford, J.A., et al. (2000) "Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas", J. Clin. Oncol., 18, 1316-1323.
24. Kaminski, M.S., Zelenetz, A.D., Press, O.W., Saleh, M., Leonard, J., Fehrenbacher, L., et al. (2001) "Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas", J. Clin. Oncol., 19, 3918-3928.
25. Gregory, S., Coleman, M., Ali, A., O'Brien, T.M., Subramanian, A., Kostakoglu, L., et al. (2000) "Efficacy and safety of Bexxar in the expanded access study: Interim report from two institutions", Blood, 96, 2386 (Abstract 4758).
26. Grillo-Lopez, A.J. (2002) "Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma", Expert Rev. Anticancer Ther., 2, 485-493.
27. Harrington, K.J. and Epenetos, A.A. (1994) "Recent developments in radioimmunotherapy", Clin. Oncol. (R. Coll. Radiol. , 6, 391-398.
28. Harrison, A., Walker, C.A. and Parker, D. (1991) "The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates", Nuclear Medicine Biology, 18, 469-479.
29. Roselli, M., Schlom, J., Gansow, O.A., Brechbiel, M.W., Mirzadeh, S., Pippin, C.G., et al. (1991) "Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies", Int. J. Rad. Appl. Instrum. B, 18, 389-394.
30. Sharkey, R.M., Motta-Hennessy, C., Gansow, O.A., Brechbiel, M.W., Fand, I., Griffiths, G.L., et al. (1990) "Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice", Int. J. Cancer, 46, 79-85.
31. Kozak, R.W., Raubitschek, A., Mirzadeh, S., Brechbiel, M.W., Junghans, R.P., Gansow, O.A., et al. (1989) "Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity", Cancer Res., 49, 2639-2644.
32. Press, W.O. (2000) "Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma", Semin. Hematol., 37, 2-8.
33. Krasner, C. and Joyce, R.M. (2001) "Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma", Curr. Pharm. Biotechnol., 2, 341-349.
34. Wiseman, G.A., White, C.A., Witzig, T.E., Gordon, L.I., Emmanouilides, C., Raubitschek, A., et al. (1999) "Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody", Clin. Cancer Res., 5, 3281s-3286s.
35. Witzig, T.E., White, C.A., Wiseman, G.A., Gordon, L.I., Emmanouilides, C., Raubitschek, A., et al. (1999) "Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20( + ) B-cell non-Hodgkin's lymphoma", J. Clin. Oncol., 17, 3793-3803.
36. Wiseman, G.A., Gordon, L.I., Multani, P.S., Witzig, T.E., Spies, S., Bartlett, N.L., et al. (2002) "Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial", Blood, 99, 4336-4342.
37. Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., et al. (2002) "Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 3262-3269.
38. Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., et al. (2002) "Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 2453-2463.
39. Schilder, R.J., Witzig, T., Gordon, L., Emmanouilides, C.E., Bartlett, N.L., Flinn, I.W., et al. (2002) "90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma", Proc. Am. Soc. Clin. Oncol., 21, 276a (Abstract 1064).
40. Gordon, L., Witzig, T., Schilder, R., Bartlett, N., Emmanouilides, C., Multani, P., et al. (2001) "High-dose therapy can be safely and successfully administered after Zevalin treatment", Proc. Am. Soc. Clin. Oncol., 20, 232b (Abstract 2681).
41. Ansell, S.M., Ristow, K.M., Habermann, T.M., Wiseman, G.A. and Witzig, T.E. (2002) "Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 3885-3890.
42. Emmanouilides, C., Witzig, T., Molina, A., Gordon, L., Multani, P., Wiseman, G., et al. (2003) "Improved safety and efficacy of Y-90-ibritumomab tiuxetan (Zevalin) radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low grade, follicular and transformed B-cell non-Hodgkin's lymphoma (NHL)", Proc. Am. Soc. Clin. Oncol., 22, 595 (Abstract 2392).
43. Flinn, I.W., Witzig, T.E., White, C.A., Gordon, L., Emmanouilides, C., Cripe, L.D., et al. (2001) "The Zevalin radioimmunotherapy (RIT) regimen is active in heavily pre-treated, bulky, rituximab refractory NHL", Proc. Am. Soc. Clin. Oncol., 20, 286a (Abstract 1141).
44. Emmanouilides, C., Witzig, T., Gordon, L., Wiseman, G., Bartlett, N., Murray, J., et al. (2001) "Zevalin radioimmunotherapy (RIT) is safe and effective in geriatric patients with low-grade, follicular or CD20 + transformed (LG/F/T) non-Hodgkin's lymphoma (NHL ", Proc. Am. Soc. Clin. Oncol., 20, 286a (Abstract 1143).
45. Wiseman, G.A., Kornmehl, E., Leigh, B., Erwin, W.D., Podoloff, D.A., Spies, S., et al. (2003) "Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials", J. Nucl. Med., 44, 465-474.
46. Wiseman, G.A., Leigh, B.R. and Erwin, W.D. (2001) "Urinary clearance of 90Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin's lymphoma", Journal of Nuclear Medicine, 42, 286P.
47. Witzig, T.E., White, C.A., Gordon, L.I., Wiseman, G.A., Emmanouilides, C., Murray, J.L., et al. (2003) "Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma", J. Clin. Oncol., 21, 1263-1270.
48. Czuczman, M., Witzig, T.E., Gaston, I., Skikne, B.S., Dimitrov, G., Gordon, L.I., et al. (2002) "Zevalin radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)", Blood, 100, 375a (Abstract 1386).
49. Wiseman, G.A., Colgan, J.P., Inwards, D.J., Micallef, I.N.M., Gansen, D.N., Porrata, L.F., et al. (2002) "Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell non-Hodgkin's lymphoma (NHL): Preliminary results", Blood, 100, 358a (Abstract 1387).
50. Witzig, T., Emmanouilides, C., Molina, A., Gordon, L., Gaston, I., Flinn, I.W., et al. (2003) "Yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) induces durable complete responses (CR/CRu) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)", Proc. Am. Soc. Clin. Oncol., 22, 579 (Abstract